Information for "Continuing development of your PARP inhibitor talazoparib for the treatment of advanced BRCA1 along with BRCA2 mutated breast cancer"
From EECH Central
Basic information
Display title | Continuing development of your PARP inhibitor talazoparib for the treatment of advanced BRCA1 along with BRCA2 mutated breast cancer |
Default sort key | Continuing development of your PARP inhibitor talazoparib for the treatment of advanced BRCA1 along with BRCA2 mutated breast cancer |
Page length (in bytes) | 3,467 |
Page ID | 1381081 |
Page content language | English (en) |
Page content model | wikitext |
Indexing by robots | Allowed |
Number of redirects to this page | 0 |
Page protection
Edit | Allow all users (infinite) |
Move | Allow all users (infinite) |
Edit history
Page creator | Sofaraven46 (Talk | contribs) |
Date of page creation | 08:25, 19 April 2024 |
Latest editor | Sofaraven46 (Talk | contribs) |
Date of latest edit | 08:25, 19 April 2024 |
Total number of edits | 1 |
Total number of distinct authors | 1 |
Recent number of edits (within past 90 days) | 1 |
Recent number of distinct authors | 1 |